Logo image of BCRX

BIOCRYST PHARMACEUTICALS INC (BCRX) Stock Fundamental Analysis

NASDAQ:BCRX - Nasdaq - US09058V1035 - Common Stock - Currency: USD

8.39  +0.17 (+2.07%)

After market: 8.39 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BCRX. BCRX was compared to 567 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BCRX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BCRX had negative earnings in the past year.
In the past year BCRX has reported a negative cash flow from operations.
In the past 5 years BCRX always reported negative net income.
In the past 5 years BCRX always reported negative operating cash flow.
BCRX Yearly Net Income VS EBIT VS OCF VS FCFBCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -18.12%, BCRX belongs to the top of the industry, outperforming 80.07% of the companies in the same industry.
Industry RankSector Rank
ROA -18.12%
ROE N/A
ROIC N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCRX Yearly ROA, ROE, ROICBCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Gross Margin of BCRX (97.23%) is better than 96.12% of its industry peers.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
BCRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
BCRX Yearly Profit, Operating, Gross MarginsBCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BCRX has been increased compared to 1 year ago.
BCRX has more shares outstanding than it did 5 years ago.
BCRX has a worse debt/assets ratio than last year.
BCRX Yearly Shares OutstandingBCRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BCRX Yearly Total Debt VS Total AssetsBCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -2.42, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
BCRX has a Altman-Z score of -2.42. This is comparable to the rest of the industry: BCRX outperforms 52.38% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.42
ROIC/WACCN/A
WACC9.34%
BCRX Yearly LT Debt VS Equity VS FCFBCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 2.63 indicates that BCRX has no problem at all paying its short term obligations.
BCRX has a Current ratio of 2.63. This is in the lower half of the industry: BCRX underperforms 69.31% of its industry peers.
A Quick Ratio of 2.58 indicates that BCRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.58, BCRX is doing worse than 68.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.58
BCRX Yearly Current Assets VS Current LiabilitesBCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

BCRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.57%, which is quite impressive.
Looking at the last year, BCRX shows a very strong growth in Revenue. The Revenue has grown by 36.00%.
The Revenue has been growing by 55.99% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)56.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.57%
Revenue 1Y (TTM)36%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%40.83%

3.2 Future

Based on estimates for the next years, BCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 40.34% on average per year.
Based on estimates for the next years, BCRX will show a quite strong growth in Revenue. The Revenue will grow by 15.39% on average per year.
EPS Next Y81.69%
EPS Next 2Y58.9%
EPS Next 3Y58.82%
EPS Next 5Y40.34%
Revenue Next Year25.39%
Revenue Next 2Y19.25%
Revenue Next 3Y17.46%
Revenue Next 5Y15.39%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BCRX Yearly Revenue VS EstimatesBCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
BCRX Yearly EPS VS EstimatesBCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCRX. In the last year negative earnings were reported.
Also next year BCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCRX Price Earnings VS Forward Price EarningsBCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCRX Per share dataBCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

BCRX's earnings are expected to grow with 58.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y58.82%

More info and screens

0

5. Dividend

5.1 Amount

BCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (4/25/2025, 8:00:01 PM)

After market: 8.39 0 (0%)

8.39

+0.17 (+2.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2025-02-24/bmo
Earnings (Next)05-05 2025-05-05/bmo
Inst Owners80.14%
Inst Owner Change0.03%
Ins Owners1.42%
Ins Owner Change16.77%
Market Cap1.75B
Analysts83.33
Price Target15.73 (87.49%)
Short Float %10.25%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-65.05%
Min EPS beat(2)-123.6%
Max EPS beat(2)-6.5%
EPS beat(4)2
Avg EPS beat(4)-10.72%
Min EPS beat(4)-123.6%
Max EPS beat(4)66.23%
EPS beat(8)4
Avg EPS beat(8)-3.77%
EPS beat(12)6
Avg EPS beat(12)-10.52%
EPS beat(16)8
Avg EPS beat(16)-5.99%
Revenue beat(2)1
Avg Revenue beat(2)0.56%
Min Revenue beat(2)-0.92%
Max Revenue beat(2)2.03%
Revenue beat(4)3
Avg Revenue beat(4)4.09%
Min Revenue beat(4)-0.92%
Max Revenue beat(4)9.02%
Revenue beat(8)4
Avg Revenue beat(8)1.37%
Revenue beat(12)5
Avg Revenue beat(12)0.74%
Revenue beat(16)8
Avg Revenue beat(16)11.47%
PT rev (1m)0%
PT rev (3m)4.04%
EPS NQ rev (1m)-0.26%
EPS NQ rev (3m)2.6%
EPS NY rev (1m)2.07%
EPS NY rev (3m)-4.71%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)6.49%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)3.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.43
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS2.16
BVpS-2.28
TBVpS-2.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -18.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.23%
FCFM N/A
ROA(3y)-35.62%
ROA(5y)-38.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.65%
GM growth 5Y1.2%
F-Score3
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.21%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.58
Altman-Z -2.42
F-Score3
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)104.99%
Cap/Depr(5y)137.87%
Cap/Sales(3y)0.47%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.57%
EPS Next Y81.69%
EPS Next 2Y58.9%
EPS Next 3Y58.82%
EPS Next 5Y40.34%
Revenue 1Y (TTM)36%
Revenue growth 3Y42.06%
Revenue growth 5Y55.99%
Sales Q2Q%40.83%
Revenue Next Year25.39%
Revenue Next 2Y19.25%
Revenue Next 3Y17.46%
Revenue Next 5Y15.39%
EBIT growth 1Y97.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year325.94%
EBIT Next 3Y110.92%
EBIT Next 5YN/A
FCF growth 1Y45.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.32%
OCF growth 3YN/A
OCF growth 5YN/A